394 related articles for article (PubMed ID: 30387894)
1. Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method.
Azar P; Nikoo M; Miles I
Am J Addict; 2018 Dec; 27(8):601-604. PubMed ID: 30387894
[TBL] [Abstract][Full Text] [Related]
2. Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.
Klaire S; Zivanovic R; Barbic SP; Sandhu R; Mathew N; Azar P
Am J Addict; 2019 Jul; 28(4):262-265. PubMed ID: 30901127
[TBL] [Abstract][Full Text] [Related]
3. Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.
Antoine D; Huhn AS; Strain EC; Turner G; Jardot J; Hammond AS; Dunn KE
Am J Addict; 2021 Jan; 30(1):83-87. PubMed ID: 32572978
[TBL] [Abstract][Full Text] [Related]
4. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
5. Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder.
Azar P; Schneiderman H; Barron H; Wong JSH; Meyer M; Newman-Azar D; Narimani M; Ignaszewski MJ; Mathew N; Mullen R; Krausz RM; Maharaj AR
Addict Sci Clin Pract; 2024 Jun; 19(1):50. PubMed ID: 38886826
[TBL] [Abstract][Full Text] [Related]
6. Novel Uses of Methadone Under the "72-Hour Rule" to Facilitate Transitions of Care and Low-Dose Buprenorphine Induction in an Outpatient Bridge Clinic.
Shahlapour M; Singh S; Christine PJ; Laks J; Evans J; Farrell NM; Khan GK; Taylor JL; Rozansky H
J Addict Med; 2024 May-Jun 01; 18(3):345-347. PubMed ID: 38329815
[TBL] [Abstract][Full Text] [Related]
7. A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder.
Azar P; Wong JSH; Jassemi S; Moore E; Vo DX; Nikoo M; Young S
Am J Addict; 2020 Nov; 29(6):531-535. PubMed ID: 32346944
[TBL] [Abstract][Full Text] [Related]
8. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Evaluation of Inpatient Transfer from High-Dose Methadone to Buprenorphine Substitution Therapy.
Oretti R
J Subst Abuse Treat; 2015 Oct; 57():102-5. PubMed ID: 26048187
[TBL] [Abstract][Full Text] [Related]
11. Rapid Induction Therapy for Opioid-Use Disorder Using Buprenorphine Transdermal Patch: A Case Series.
Saal D; Lee F
Perm J; 2020; 24():. PubMed ID: 32240088
[TBL] [Abstract][Full Text] [Related]
12. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
Coish R; Hardial J
J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416
[TBL] [Abstract][Full Text] [Related]
13. Case Series: Limited Opioid Withdrawal With Use of Transdermal Buprenorphine to Bridge to Sublingual Buprenorphine in Hospitalized Patients.
Tang VM; Lam-Shang-Leen J; Brothers TD; Hansen K; Caudarella A; Lamba W; Guimond T
Am J Addict; 2020 Jan; 29(1):73-76. PubMed ID: 31626394
[TBL] [Abstract][Full Text] [Related]
14. Transition From Methadone to Buprenorphine Using a Short-acting Agonist Bridge in the Inpatient Setting: A Case Study.
Callan J; Pytell J; Ross J; Rastegar DA
J Addict Med; 2020; 14(5):e274-e276. PubMed ID: 31977358
[TBL] [Abstract][Full Text] [Related]
15. Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial.
Wong JSH; Nikoo M; Westenberg JN; Suen JG; Wong JYC; Krausz RM; Schütz CG; Vogel M; Sidhu JA; Moe J; Arishenkoff S; Griesdale D; Mathew N; Azar P
Addict Sci Clin Pract; 2021 Feb; 16(1):11. PubMed ID: 33579359
[TBL] [Abstract][Full Text] [Related]
16. Rapid Transition to Buprenorphine in a Patient With Methadone-Related QTc Interval Prolongation.
Brogdon H; Facer KL; Cox EJ; Carlson RH; Wurzel JF
J Addict Med; 2022 Jul-Aug 01; 16(4):488-491. PubMed ID: 34864786
[TBL] [Abstract][Full Text] [Related]
17. Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.
Thakrar AP; Uritsky TJ; Christopher C; Winston A; Ronning K; Sigueza AL; Caputo A; McFadden R; Olenik JM; Perrone J; Delgado MK; Lowenstein M; Compton P
Addict Sci Clin Pract; 2023 Feb; 18(1):13. PubMed ID: 36829242
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine microdosing regimen using transdermal buprenorphine patches to transition from methadone to buprenorphine.
Naren T; Cook J; MacCartney P; Membrey D
Drug Alcohol Rev; 2024 May; 43(4):1013-1018. PubMed ID: 38408741
[TBL] [Abstract][Full Text] [Related]
19. Use of a novel prescribing approach for the treatment of opioid use disorder: Buprenorphine/naloxone micro-dosing - a case series.
Brar R; Fairbairn N; Sutherland C; Nolan S
Drug Alcohol Rev; 2020 Jul; 39(5):588-594. PubMed ID: 32657496
[TBL] [Abstract][Full Text] [Related]
20. Community based buprenorphine micro-induction in the context of methadone maintenance treatment and fentanyl - Case report.
Kaliamurthy S; Jegede O; Hermes G
J Addict Dis; 2023; 41(2):175-180. PubMed ID: 35377273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
